Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

NetraMark’s Powerful AI Data Analysis and Machine Learning to Power the Nuro App

Nurosene Health, the leading provider of brain health technology and services, has agreed to sign a deal to acquire AI enabler, NetraMark. NetraMark, a Canadian startup, currently offers proprietary A.I. and machine learning solutions to pharma and biotech companies.

NetraMark's powerful AI data analysis and machine learning to power the Nuro appBy acquiring NetraMark’s innovative A.I. solutions and machine learning capabilities, Nurosene will further expand on its mission for better brain health. Together, the health technology pair will work to provide critical predictive analysis that will inform “our community’s health and wellness.”

Currently, Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.

At the time of this significantly transformative development, Nurosene’s CEO, Ranj Bath, commented, “We are looking forward to adding NetraMark’s talented technology team led by Dr. Joseph Geraci, whose proprietary machine learning capabilities will evolve and advance Nurosene’s mission for better brain health. Based on NetraMark’s powerful data analysis and machine learning capabilities, NetraAI will power the Nuro app, which will not only extract extensive data and research but interpret that data quickly, providing a predictive component for our community’s health and wellness. These insights will be invaluable in supporting Nurosene to continue designing precision solutions, such as drug development, to address mental health challenges and other complex disorders.”

Biotech Company Theravab to Implement IP Management on dClinic’s Blockchain

Dr. Joseph Geraci, PhD, Founder and CEO of NetraMark added, “Nurosene provides a platform and team that we can leverage to further market and transform our proprietary technology. Together we want to build a future for health and wellness that will advance precision medicine and drug development with the goal to develop new and personalized preventative therapeutics. By building upon the established AI and data-driven techniques of NetraMark’s products, we can effectively accelerate Nurosene’s mission to improve mental wellness by evaluating and predicting optimal treatments and therapeutic formulations in collaboration with their proprietary mobile application.”

Related Posts
1 of 33,766

NetraMark has developed proprietary artificial intelligence (“AI”) and machine learning solutions to accelerate drug discovery for pharmaceutical companies. Their deep tech AI engine has the ability to leverage small to large datasets from user populations. This allows for the extraction of meaningful insights, designed to have a deep impact on precision treatments, leading to improved patient outcomes and discoveries.

University of Florida Accelerates BioTech Research Innovation with Qumulo

Dr Joseph Geraci, PhD is a mathematician, medical scientist, and quantum machine learning specialist. He holds postdocs in machine learning, oncology and neuropsychiatry. He has developed novel machine intelligence algorithms that are capable of providing extraordinary insights into complex data sets, like those found in clinical trials. He is associated with the department of Molecular Medicine and Pathology at Queen’s University in Ontario, Canada, and the Centre for Biotechnology and Genomics Medicine Medical College of Georgia, USA.

NetraMark Corp., an AI and pharma-tech company, has developed proprietary solutions for pharmaceutical and biotechnology companies. These solutions allow them to leverage their small to large data in order to optimize clinical trials and drug development. This is accomplished by providing a superior understanding of their patient populations and these insights are also used to develop new drugs and nutraceuticals.

Founded in 2016 by Dr. Joseph Geraci, PhD, and Richard M. Brooks, LLB, NetraMark was built to address current gaps in the pharmaceutical market. Utilizing AI and machine learning, NetraMark provides powerful insights into how to treat patients at the individual level, instead of a ‘one size fits all’ model. NetraMark was built to accelerate the path towards new medications and nutraceuticals through leveraging the full extent of AI and machine learning.

[To share your insights with us, please write to]

Comments are closed.